Supplementary information

Depsipeptide Aspergillicins Revealed by Chromatin Reader Protein

Deletion

- 4 C. Greco,^a B. T. Pfannenstiel,^b J. C. Liu^a and N. P. Keller^{a,c}
- a Department of Medical Microbiology and Immunology, University of Wisconsin-Madison, Madison, WI, USA
- ^b Department of Genetics, University of Wisconsin-Madison, Madison, WI, USA
- ^c Department of Bacteriology, University of Wisconsin-Madison, Madison, WI, USA

Contents

- bp). ∆*sidJ*[; T2 correct LH \(2426 bp\), RH \(2005 bp\), and no product in purity test \(2490 bp\). ∆](#page-13-1)*agiB*; [T1, T2, T3, T4, T5 correct LH \(2861 bp\), RH \(1730 bp\), and no product in purity test \(3034 bp\).](#page-13-1)
- [...14](#page-13-1)
- [Figure S12. A\) Semi-qPCR analysis for](#page-14-1) *agiA*, *agiB*, *sidJ*, *sidF* and acting (expected products 100- [120 bp\). B\) Bar charts showing relative expression of](#page-14-1) *agiA*, *agiB* and *sidJ* using normalized
- expression ration (2 -∆∆Ct Method) between WT and ∆*sntB*[...15](#page-14-1)

List of Tables

[Table S5. NMR assignment of aspergillicin G 11 \(](#page-21-0)^a150 MHz, ^b600 MHz in CDCl₃).22

Experimental section

General procedures

 Analytical grade chemicals and reagents were supplied from Sigma-Aldrich, Alfa Aesar, Acros Organics and Fischer, unless otherwise stated. Solvents used for HPLC-DAD analyses were HPLC grade, and for UPLC-HRMS analysis were LCMS grade. General molecular biology procedures were performed as standard and molecular biology kits used according to manufacturer's protocols. Analytical PCR was performed using PfuII Ultra high fidelity (Agilent) Expand Long Template PCR (Roche) DNA polymerases.

NMR

 NMR experiments were conducted on the following spectrometers: Bruker Avance-500 DCH 104 cryoprobe (¹H NMR at 500 MHz and ¹³C NMR at 125 MHz), Bruker Avance-600 TCI-F cryoprobe 105 (¹H NMR at 500 MHz and ¹³C NMR at 150 MHz). Chemical shifts were recorded in parts per million (ppm referenced to the appropriate residual solvent peak).

HPLC-DAD

 HPLC-DAD for analysis and purification was performed on Gilson GX-271 Liquid Handler with system 322 H2 Pump connected to a 171 Gilson Diode Array Detector and fraction collector. A XBridge BEH C18 XP Column (130 Å, 2.5 µm, 4.6 mm x 100 mm) with XBridge BEH C18 XP VanGuard Cartridge (130 Å, 2.5 µm, 3.9 mm x 5 mm) was used for analytical run with a flow rate of 0.8 mL/min. A XBridge BEH C18 OBD Prep Column (130 Å, 5 µm, 19 mm x 250 mm) with a XBridge BEH C18 Prep Guard Cartridge (130 Å, 5 µm, 19 mm x 10 mm) was used for preparative run with flow rate of 16 mL/min. HPLC grade water with 0.5% formic acid (solvent A) and HPLC grade acetonitrile with 0.5% formic acid (solvent B) were used with the following gradient 0 min, 20% Solvent B; 2 min, 20% Solvent B; 15 min, 95% Solvent B; 20 min, 95% Solvent B; 20 min, 20% Solvent B; 25 min, Solvent B. Data acquisition and procession for the HPLC-DAD were 118 controlled by TRILUTION LC V3.0.

UHPLC-HRMS

 UHPLC-HRMS was performed on a Thermo Scientific-Vanquish UHPLC system connected to a 121 Thermo Scientific Q Exactive Orbitrap mass spectrometer in ES⁺ and ES⁻ mode between 200 m/z and 1000 m/z to identify metabolites. A Zorbax Eclipse XDB-C18 column (2.1 × 150 mm, 1.8 μm particle size) was used with a flow rate of 0.2 mL/min for all samples. LCMS grade water with 0.5% formic acid (solvent A) and LCMS grade acetonitrile with 0.5% formic acid (solvent B) were used with the following gradient 0 min, 20% Solvent B; 2 min, 20% Solvent B; 15 min, 95% Solvent B; 20 min, 95% Solvent B; 20 min, 20% Solvent B; 25 min, Solvent B. Nitrogen was used as the sheath gas. Data acquisition and procession for the UHPLC-MS were controlled by Thermo Scientific Xcalibur software.

129 **Fungal strains and media**

130 Strains used in this study are listed in Supplementary Table S1. They were grown on glucose \parallel 31 minimal media (GMM)¹ with additional supplements for auxotrophic strains. Solid and liquid 132 cultures were grown in a light incubator at 30 °C. All strains were maintained as glycerol stocks

133 at −80 °C. Strain TJW149 is used as our wild-type control unless otherwise noted.

134

- 135 **Figure S1.** *A. flavus* ∆*sntB* (left) and wild type (right) strains grown on GMM for 6 days at 30 °C.
- 136 **Table S1.** List of strain used in this work.

137

138 **DNA fragment construction for gene disruption**

139 All the DNA constructs were prepared using double joint PCR.⁴ 1 to 2 kb of 5' and 3' flanking sequence of each gene of interest was amplified using oligonucleotides listed in [Table S2](#page-6-0) (i.e., 5′-F paired with 5′-R) from RAAS233.2 genomic DNA, with the *pyrG* marker amplified from genomic DNA isolated from *A. fumigatus*. These fragments were then fused together *via* PCR to

- 143 generate deletion constructs. PCR amplification was carried out on a C1000TM Thermal Cycler
- 144 (BioNRad).
- 145 **Table S2.** List of oligonucleotides

147 **Growth conditions and method of extraction**

 The *A. flavus* strains were grown on glucose minimal media (GMM), potato dextrose agar (PDA) 149 or potato dextrose broth (PDB) for 14 days at 30 °C, the liquid culture was shaken at 200 rpm. Each 25 mL plate was blended in ethyl acetate (100 mL) and water (50 mL). After two hours, the solid was removed using vacuum filtration and the organic layer was separated. The aqueous layer was extracted with ethyl acetate (2 x 25 mL). The combined organic phases were dried over anhydrous magnesium sulfate and concentrated under reduced pressure. To a liquid PDB culture (200 mL), ethyl acetate (300 mL) was added. The mixture was blended and left soaking for 2 hours. The mycelia were removed by vacuum filtration, the organic layer was removed, and the aqueous layer was extracted with ethyl acetated (2 x 100 mL). The combined organic phases were dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The dried extracts were resuspended in LCMS grade acetonitrile at a concentration of 10 mg/mL and filtered through an Acrodisc syringe filter with a nylon membrane (Pall Corporation) (0.45 μm pore 160 size).

- 161 **Bioinformatic analysis**
- 162 **Analysis cluster**

164 **Figure S2.** Schematic of the aspergllicin BGC flanked by siderophores genes.

165 **Table S3.** Summary of the predicted functions for the genes in the putative aspergillicin cluster. The function was determined using NCBI BLAST in non-redundant database.

Artemis comparison tool (ACT) analysis

- 168 ACT⁵ was used to compare the aspergillicin BGC from *A. flavus*, to the genome of *A. fumigatus*,
- *A. oryzae*, *A. arachhidicola* and *A. nidulans*. The red and blue lines indicate homologous genes
- with identity above 75%.

Figure S5. ACT analysis of the aspergillicin BGC from *A. flavus* genome *vs A. nidulans*.

Figure S6. ACT analysis of the aspergillicin BGC from *A. flavus* genome *vs A. fumigatus*.

Multigene BLAST

- 182 Multigene BLAST⁶ analysis identified that the siderophore BGC is fairly conserved across many
- fungi. But the NRPS *agiA* is unique to *A. flavus* and closely related species.

 Figure S7. Multigene BLAST analysis of the aspergillicin BGC. The siderophore genes can be identified across different fungi.

Analysis of condensation domain

Multiple sequence alignment using Clustal Omega of the condensation domains of AgiA

(AFLA_010580) revealed the canonical HHxxxDG motif.

CLUSTAL 0(1.2.4) multiple sequence alignment

Figure S8. Multiple sequence aligment done using Clustal Omega. Red box highiligts conserved motif.

Analysis of the thioesterase (TE) domains

 Phylogenetic analysis of the *agiA* TE domain was done using Clustal Omega and iTOL with defaults parameters [\(Figure S9\)](#page-11-2). The TE domain is clearly distinct from condensation domains. There is not a clear distinction among bacterial TE domains in PKS or NRPS genes. In contrast, fungal TE domains in PKS genes are clustered together. Not many TE domains from fungal NRPS are available, but agiA-TE is very closely related to another fungal NRPS-TE involved in the biosynthesis of penicillin. Interestingly, the two fungal NRPS-TE clustered more closely to the bacterial TE domains than the fungal PKS TE domains.

202 **Figure S9.** Phylogenetic tree for the TE domains (orange) and C domains (blue). Dark orange highlights fungal NRPS-
203 TE domains. The TE domains is divided in bacterial TEs. fungal NRPS-TE and fungal PKS-TE domains. TE domains. The TE domains is divided in bacterial TEs, fungal NRPS-TE and fungal PKS-TE domains.

Fungal transformation

205 A fresh spore suspension (2 x 10 6 spores/mL) of TXZ13 was used to inoculate 500 mL of sterile GMM and shaken at 280 rpm and 28 °C until the formation of young germlings (~13 hours). The 207 germlings were centrifuged at 8000 rpm for 15 mins at 4 °C. The supernatant was discarded and 208 50 mL of sterile dH₂O water was added to the germlings. They were spin at 8000 rpm for 15 mins at 4 °C. The supernatant was removed and the germlings were transferred to 10 mL of osmotic 210 medium (1.2 M MgSO₄, 10 mM NAPB^{*}), adjusted to pH 5.8 with 1 M Na₂HPO₄) with 30 mg of Lysing Enzymes (Sigma) and 20 mg of Yatalase (TaKaRa). The germlings were then shaken at 80 rpm and 28 °C, until protoplasts were obtained (approx. 3 h). The protoplast solution (10 mL) were transferred to a 30 mL cortex tube and very gently overlaid with 10 mL of trapping buffer (0.6 M sorbitol and 0.1 M Tris-HCI, pH 7.0). After centrifugation in the HB-4 (or Beckmann 215 equivalent) rotor at 5000 rpm for 15 min at 4 °C, the protoplasts were removed from the interface and transferred to a 15 mL sterile tube. The protoplasts were diluted with one volume of STC 217 buffer (1.2 M sorbitol, 10 mM CaCl₂, 10 mM Tris-HCI, pH 7.5) and centrifuged at 6000 rpm for 10 min at 4 °C. The supernatant was removed, and the protoplasts were resuspended in STC (1-2 mL) and stored on ice. The transforming DNA (e.g. specific gene disruption construct) was diluted 220 with STC (10 μg/100 μL) in a 15 mL falcon tube. The protoplast was added to the DNA (100 μL) and incubated on ice for 50 minutes. Then 1.25 mL of PEG solution (60% PEG 4000, 50 mM 222 CaCl², 50 mM 10 mM Tris-HCI, pH 7.5) was added, mixed gently and incubated at room temperature for 20 minutes. Next 5 mL of STC was added to the mixture, gently mixed and the entirety plated (500 μL) on GMM media containing sorbitol (1.2 M). Resulting transformants were subcultured twice on selective media and confirmed by Southern and PCR.

226 *NaPB: 2M phosphate buffer = 90.9 g Na₂HPO₄ and 163.4 g NaH₂PO₄ per liter, with pH 6.5.

Transformant confirmation

 The transformants were confirmed using Southern analysis for the *∆agiA* strain [\(Figure S10\)](#page-12-1) and PCR analysis for *∆agiB*, *∆sidJ* and *∆agiF* [\(Figure S11\)](#page-13-1). Primers used are listed on [Table S3.](#page-7-3)

Figure S11. PCR confirmation of the correct disruption of the resistance and purity. Schematic of the expected product 234 (left). Gel for the transfromants C = control; W = water, T = transfromants. Purity test indi 234 (left). Gel for the transfromants C = control; W = water, T = transfromants. Purity test indicates primer that amplify the 235 ORF, and no product should be observed in the correct transfromants. \triangle *agiB*; T1 correc ORF, and no product should be observed in the correct transfromants. ∆*agiB*; T1 correct LH (2500 bp), RH (1744 bp), 236 and no product in purity test (1286 bp). ∆*sidJ*; T2 correct LH (2426 bp), RH (2005 bp), and no product in purity test (3034 bp).
237 (2490 bp). ∆*agiB*; T1, T2, T3, T4, T5 correct LH (2861 bp), RH (1730 bp), and no p (2490 bp). ∆*agiB*; T1, T2, T3, T4, T5 correct LH (2861 bp), RH (1730 bp), and no product in purity test (3034 bp).

Reverse transcriptase quantitative PCR (RT-qPCR)

 The wild- type and ∆*sntB* strains were grown in liquid PDB media at 30 °C and 200 rpm. RNA was extracted at day 2, 3 and 6 from lyophilized tissues using Trizol (Invitrogen). For RT-qPCR, RNA was quantified and 10 μg was DNaseI treated before cDNA synthesis using iScript (Bio-Rad). Primers used in qPCR are listed (Table S2). qPCR was performed using iQ SYBR Green Supermix (BIO-RAD) and CFX Connect Real-Time System machine (BIO-RAD). Program used considted of: (1) 95 °C for 3 minutes; (2) 95 °C for 30 seconds; (3) 55 °C for 30 seconds; Steps 2-3 were repeated 39 times.

The relative quantification of gene expression using 2^{-∆∆C}T (Livak) method. **(1)** The C_T value of the 247 target gene from the ∆*sntB* was normalized to reference gene (actin). (2) Then the C_T from WT of the target gene was normalized to reference gene (actin). **(3-4)** The Normalized expression ratio was calculated.

- 250 (1) $\Delta C_{T(test)} = C_{T(target)} C_{T(ref, test)}$
- 251 (2) $\Delta C_{T(calibration)} = C_{T(target, \; calibration)} C_{T(ref., \; calibration)}$
- 252 (3) $\Delta \Delta C_T = \Delta C_{T(test)} \Delta C_{T(calibrated)}$
- $(4) 2^{-\Delta\Delta C_T} = Normalized$ expression ratio

Figure S12. Bar charts showing relative expression of *agiA*, *agiB* and *sidJ* using normalized expression ration (2^{-∆∆Ct}
256 Method) between WT and ∆sntB. Method) between WT and ∆*sntB*.

Feeding experiment

The ∆*sntB/*∆*agiB* strain was inoculated to six 500 mL flasks, each containing 200 mL of PDB.

They were grown at 30 °C with shaking at 200 rpm. A solution of *O*-Me-L-tyrosine in water (200

mg/10 mL) was divided over three flasks and added over three days (day 6, 7, 8). Each flask was

extracted separately with ethyl acetated. The six extracts (three fed with *O*-Me-L-tyrosine) were

analyzed by UPLC-HRMS [\(Figure S13\)](#page-15-1).

 Figure S13. Summary of the feeding experiment using *O-*Me-L-tyrosine. ∆*sntB* produces aspergillicn A **1** and F **2**. ∆*sntB*∆*agiB* produces aspergillicin C **4** and aspergillicin G **11**. ∆*sntB*∆*agiB* plus *O*-Me-tyrosine produces aspergillicin A **1** and aspergillicin F **2**.

Sensitivity to iron experiment

The wild type and all the deletion strains were serially passaged for three times on GMM lacking

269 iron and then plated on plates containing either no iron, normal growth media level of $FeSO₄$ (5

270 μ M), high level of FeSO₄ (1 mM) and very high level of FeSO₄ (10 mM). The plates were grown

271 for 5 days at 30 °C and their growth was evaluated.

Isolations of aspergillicins

Aspergillicin A 1

 A. flavus ∆*sntB* was grown on PDA plates (10 x 25 mL) at 30 °C. After 14 days, it was extracted and purified using prep-HPLC to obtain of pure aspergillicin A **1** as faint yellow powder (1.6 mg). λ_{max} / nm 200, 220, 280; δ_H (CDCl₃, 600 MHz) 8.25 (1H, d, 8.5 Hz), 7.10-7.08 (1H, m), 7.04 (2H, d, 8.5 Hz), 6.84 (2H, d, 8.5), 6.62 (1H, d, 9.5 Hz), 5.56 (1H, m), 4.95 (1H, dd, 11.5, 3.3 Hz), 4.86 (1H, dd, 10.0, 2.5 Hz), 4.62 (1H, dd, 9.5, 7.2 Hz), 4.52 (1H, dd, 9.2, 5.2 Hz), 4.42 (1H, dd, 8.5, 5.9 Hz), 4.32 (1H, dd, 8.5, 5.2), 3.78(3H, s), 3.70-3.63 (2H, m), 3.58-3.49 (2H, m), 2.16 (3H, s), 2.20- 2.08 (3H, m), 2.0-1.8 (4H, m), 1.74-1.70 (2H, m), 1.39-1.37 (1H, m), **1.30** (3H, m), **1.0-0.85** (13H, 285 m); δ_C (CDCl₃, 150 MHz) 173.4, 171.3, 171.25, 170.4, 170.2, 169., 168.6, 130.7 (2C), 130.5, 114.5 (2C), **72.0**, 62.7, 59.0, 58.4, 47.6, 47.5, **47.8**, 38.1, 33.6, 30.5, 29.5, **28.7, 28.0, 26.2, 25.6, 24.8, 23., 19.6, 18.4, 16.7, 14.3, 11.9**; m/z (ESI) 741.4175 [M+H]⁺ (C₃₈H₅₆N₆O₉ requires 741.4187). 288 Data in accordance to the literature.⁸ chemical shifts in **bold** were identified using HSQC/HMBC.

Aspergillicin F 2

 A. flavus ∆*sntB* was grown on PDA plates (10 x 25 mL) at 30 °C. After 14 days, it was extracted and purified using prep-HPLC to obtain of pure aspergillicin F **2** as faint yellow powder (8 mg).

- 293 λ_{max} / nm 200, 220, 280; δ_H (CDCl₃, 600 MHz) and δ_C (CDCl₃, 150 MHz) see [Table S4;](#page-20-1) m/z (ESI)
- 294 755.4337 [M+H]⁺ (C₃₉H₅₈N₆O₉ requires 755.4343). Data in accordance to the literature.⁸

Aspergillicin C 4

 A. flavus ∆*sntB*∆*agiB* was grown on PDA plates (10 x 25 mL) at 30 °C. After 14 days, it was extracted and purified using prep-HPLC to obtain of pure aspergillicin C **4** as faint yellow powder 299 (1 mg). λ_{max} / nm 200, 220, 280; δ_H (CDCl₃, 600 MHz) 8.26 (1H, d, 8.0 Hz), 7.33-7.26 (3H, m), 7.21-7.10 (3H, m), 6.63 (1H, d, 9.7 Hz), 5.60-5.54 (1H, m), 5.01 (1H, dd, 11.8, 3.6), 4.87,(1H, dd, 10.0, 2.4 Hz), 4.63 (1H, dd, 9.6, 7.5 Hz), 4.51 (1H, m), 4.41 (1H, dd, 8.6, 6.2 Hz), 4.27 (1H, m), 3.70-3.47 (4H, m), 3.22, (1H, dd, 14.2, 3.0 Hz), 3.04 (1H, dd, 14.2, 11.5), 2.85 (3H, s), 2.17 (3H, s), 2.25-2.18 (2H, m), 2.01-1.84 (4H, m), 1.70-1.62 (2H, m), 1.43-1.38 (1H, m), 1.27 (3H, d, 15 304 Hz), 1.16-1.09 (1H, m), 1.8-0.75 (14H, m); m/z (ESI) 711.4072 [M+H]⁺ (C₃₇H₅₄N₆O₈ requires 305 711.4081). Data in accordance to the literature.⁹

Aspergillicin G 11

 A. flavus ∆*sntB*∆*agiB* was grown on PDA plates (10 x 25 mL) at 30 °C. After 14 days, it was extracted and purified using prep-HPLC to obtain of pure aspergillicin G **11** as faint yellow powder 310 (5 mg). λ_{max} / nm 200, 220, 280; ¹H NMR and ¹³C NMR data see [Table S5;](#page-21-0) m/z (ESI) 725.4232 311 [M+H]⁺ (C₃₈H₅₆N₆O₈ requires 725.4237).

HRMS and UV spectra

Figure S15. HRMS spectrum (left) and UV spectrum of aspergillicin A **1**.

Figure S17. HRMS spectrum (left) and UV spectrum of aspergillicin B **4**.

-
-
-
-

326 **NMR data**

327 Table S4. NMR assignment of aspergillicin F 2 in agreement with literature⁸ (^a150 MHz, ^b600 MHz in CDCl₃).

Figure S19. ¹H NMR of aspergillicin A **1** (600 MHz in CDCl3).

Figure S20. ¹³C NMR of aspergillicin F **1** (150 MHz in CDCl3)

Figure S21. HSQC spectrum of aspergillicin A **1** (600 MHz in CDCl3).

340 Figure S23. ¹H NMR of aspergillicin F **1** (600 MHz in CDCl₃).

Figure S24. ¹³C NMR of aspergillicin F **2** (150 MHz in CDCl3)

Figure S25. COSY spectrum of aspergillicin F **2** (600 MHz in CDCl3).

Figure S26. HSQC spectrum of aspergillicin F **2** (600 MHz in CDCl3)

Figure S27. HMBC spectrum of aspergillicin F **2** (600 MHz in CDCl3).

Figure S28. ¹H NMR of aspergillicin C **4** (600 MHz in CDCl3).

Figure S29. COSY spectrum of aspergillicin C **4** (600 MHz in CDCl3).

Figure S30. ¹³C NMR of aspergillicin G **11** (150 MHz in CDCl3).

356 **Figure S31.** ¹H NMR of aspergillicin G 11 (600 MHz in CDCl₃).

Figure S32. COSY spectrum of aspergillicin G **11** (600 MHz in CDCl3).

Figure S33. HSQC spectrum of aspergillicin G **11** (600 MHz in CDCl3).

Figure S34. HMBC spectrum of aspergillicin G **11** (600 MHz in CDCl3).

Reference

- (1) Shimizu, K.; Keller, N. P. Genetic Involvement of a CAMP-Dependent Protein Kinase in a G Protein Signaling Pathway Regulating Morphological and Chemical Transitions in *Aspergillus Nidulans*. *Genetics* **2001**, *157* (2), 591–600.
- (2) Zhao, X.; Spraker, J. E.; Bok, J. W.; Velk, T.; He, Z.-M.; Keller, N. P. A Cellular Fusion Cascade Regulated by LaeA Is Required for Sclerotial Development in *Aspergillus Flavus*. *Front. Microbiol.* **2017**, *8*, 1925. https://doi.org/10.3389/fmicb.2017.01925.
- (3) Pfannenstiel, B. T.; Zhao, X.; Wortman, J.; Wiemann, P.; Throckmorton, K.; Spraker, J. E.; Soukup, A. A.; Luo, X.; Lindner, D. L.; Lim, F. Y.; et al. Revitalization of a Forward Genetic Screen Identifies Three New Regulators of Fungal Secondary Metabolism in the Genus *Aspergillus*. *MBio* **2017**, *8* (5), e01246-17. https://doi.org/10.1128/mBio.01246-17.
- (4) Yu, J.-H.; Hamari, Z.; Han, K.-H.; Seo, J.-A.; Reyes-Domínguez, Y.; Scazzocchio, C. Double-Joint PCR: A PCR-Based Molecular Tool for Gene Manipulations in Filamentous Fungi. *Fungal Genet. Biol.* **2004**, *41* (11), 973–981. https://doi.org/10.1016/j.fgb.2004.08.001.
- (5) Carver, T. J.; Rutherford, K. M.; Berriman, M.; Rajandream, M.-A.; Barrell, B. G.; Parkhill, J. ACT: The Artemis Comparison Tool. *Bioinformatics* **2005**, *21* (16), 3422–3423. https://doi.org/10.1093/bioinformatics/bti553.
- (6) Medema, M. H.; Takano, E.; Breitling, R. Detecting Sequence Homology at the Gene Cluster Level with MultiGeneBlast. *Mol. Biol. Evol.* **2013**, *30* (5), 1218–1223. https://doi.org/10.1093/molbev/mst025.
- (7) Yelton, M. M.; Hamer, J. E.; Timberlake, W. E. Transformation of *Aspergillus nidulans* by Using a TrpC Plasmid. *Proc. Natl. Acad. Sci. U. S. A.* **1984**, *81* (5), 1470–1474.
- (8) Kikuchi, H.; Hoshikawa, T.; Fujimura, S.; Sakata, N.; Kurata, S.; Katou, Y.; Oshima, Y. Isolation of a Cyclic Depsipetide, Aspergillicin F, and Synthesis of Aspergillicins with Innate Immune-Modulating Activity. *J. Nat. Prod.* **2015**, *78* (8), 1949–1956. https://doi.org/10.1021/acs.jnatprod.5b00286.
- (9) Capon, R. J.; Skene, C.; Stewart, M.; Ford, J.; O'Hair, R. A. J.; Williams, L.; Lacey, E.; Gill, 391 J. H.; Heiland, K.; Friedel, T. Aspergillicins A-E: Five Novel Depsipeptides from the Marine-Derived Fungus *Aspergillus carneu*s. *Org. Biomol. Chem.* **2003**, *1* (11), 1856–1862.

https://doi.org/10.1039/b302306k.